ATE262909T1 - Intravenöse alendronatformulierungen - Google Patents

Intravenöse alendronatformulierungen

Info

Publication number: ATE262909T1
Authority: AT; Austria
Prior art keywords: intravenous; bone disease; alendronate formulations; formulations; intravenous alendronate
Prior art date: 1994-08-24

Application number

AT95929625T

Other languages

English (en)

Inventor

Gerald S Brenner

Musa M Ghannam

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-24

Filing date

1995-08-21

Publication date

2004-04-15

1995-08-21 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2004-04-15 Application granted granted Critical

2004-04-15 Publication of ATE262909T1 publication Critical patent/ATE262909T1/de

Links

OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title abstract 2
229940062527 alendronate Drugs 0.000 title abstract 2
238000001990 intravenous administration Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
206010020584 Hypercalcaemia of malignancy Diseases 0.000 abstract 1
208000030136 Marchiafava-Bignami Disease Diseases 0.000 abstract 1
208000029725 Metabolic bone disease Diseases 0.000 abstract 1
208000037848 Metastatic bone disease Diseases 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT95929625T 1994-08-24 1995-08-21 Intravenöse alendronatformulierungen ATE262909T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/296,192 US5780455A (en)	1994-08-24	1994-08-24	Intravenous alendronate formulations
PCT/US1995/010583 WO1996005842A1 (en)	1994-08-24	1995-08-21	Intravenous alendronate formulations

Publications (1)

Publication Number	Publication Date
ATE262909T1 true ATE262909T1 (de)	2004-04-15

Family

ID=23140992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95929625T ATE262909T1 (de)	1994-08-24	1995-08-21	Intravenöse alendronatformulierungen

Country Status (10)

Country	Link
US (3)	US5780455A (de)
EP (1)	EP0777484B1 (de)
JP (2)	JP3962429B2 (de)
AT (1)	ATE262909T1 (de)
AU (1)	AU698411B2 (de)
CA (1)	CA2197210C (de)
DE (1)	DE69532810T2 (de)
ES (1)	ES2216017T3 (de)
PT (1)	PT777484E (de)
WO (1)	WO1996005842A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU667376B2 (en) *	1992-05-21	1996-03-21	Monsanto Company	Retroviral protease inhibitors
US5780455A (en) *	1994-08-24	1998-07-14	Merck & Co., Inc.	Intravenous alendronate formulations
US5616571A (en) *	1995-06-06	1997-04-01	Merck & Co., Inc.	Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL129127A0 (en) *	1996-10-04	2000-02-17	Merck & Co Inc	Liquid alendronate formulations
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
US5994329A (en)	1997-07-22	1999-11-30	Merck & Co., Inc.	Method for inhibiting bone resorption
US6432932B1 (en)	1997-07-22	2002-08-13	Merck & Co., Inc.	Method for inhibiting bone resorption
US6331533B1 (en)	1998-11-16	2001-12-18	Merck & Co., Inc.	Method for inhibiting dental resorptive lesions
US6794536B1 (en) *	1998-12-10	2004-09-21	Aesqen, Inc.	Method for preparation of disodium pamidronate
US6677320B2 (en) *	2000-01-20	2004-01-13	Hoffmann-La Roches Inc.	Parenteral bisphosphonate composition with improved local tolerance
IL150841A0 (en) *	2000-02-09	2003-02-12	Hokuriku Pharmaceutical	1h-imidazopyridine derivatives
JP3923800B2 (ja) *	2000-05-05	2007-06-06	エフ．ホフマン−ラロシュアーゲー	ビスホスホン酸またはそれらの塩を含む、皮下投与のためのゲル様医薬組成物
AU2001292598B2 (en) *	2000-09-14	2006-06-29	Merck & Co., Inc.	Alpha V integrin receptor antagonists
KR20030043931A (ko) *	2000-09-18	2003-06-02	에프. 에이취. 펄딩 앤드 컴파니 리미티드	디포스포네이트 용액
US8721625B2 (en) *	2001-01-26	2014-05-13	Cook Medical Technologies Llc	Endovascular medical device with plurality of wires
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
AT502590A1 (de) *	2001-09-27	2007-04-15	Oekopharm Forschungs Und Entwi	Basenhältige mikronährstoffmischung
AU2003226148A1 (en) *	2002-04-05	2003-10-27	Merck & Co., Inc.	Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20050261250A1 (en) *	2004-05-19	2005-11-24	Merck & Co., Inc.,	Compositions and methods for inhibiting bone resorption
AU2005275193A1 (en) *	2004-07-15	2006-02-23	Nanobac Life Sciences	Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
US20060134190A1 (en) *	2004-12-16	2006-06-22	Banner Pharmacaps Inc.	Formulations of bisphosphonate drugs with improved bioavailability
US20060204567A1 (en) *	2005-03-08	2006-09-14	Jiang Hu	Potato proteinase inhibitor II exhibits activity in elevating fasting plasma cholecystokinin concentrations
US7605148B2 (en) *	2007-04-16	2009-10-20	Aurobindo Pharma Ltd.	Aqueous oral solution of bisphosphonic acid
US20100286038A1 (en) *	2007-09-21	2010-11-11	Valentyn Antochshuk	Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20110065672A1 (en) *	2009-09-16	2011-03-17	Mount Sinai School Of Medicine Of New York University	Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis
EP2363111A1 (de) *	2010-03-01	2011-09-07	Combino Pharm, S.L.	Stabile pharmazeutische Zusammensetzung mit Bisphosphonat
US9682090B2 (en)	2014-11-14	2017-06-20	University Of Washington	Methods for treating and preventing prostate cancer bone metastases
EP4271370A4 (de) *	2020-12-29	2024-12-04	Next Science IP Holdings Pty Ltd	Zusammensetzung und verfahren zur krebsbehandlung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06700B2 (ja) *	1986-03-27	1994-01-05	旭化成工業株式会社	安定な水性液剤
DE3623397A1 (de) *	1986-07-11	1988-01-14	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2617508B2 (ja) *	1988-02-05	1997-06-04	エーザイ株式会社	安定なジフェンヒドラミン含有水溶液
US4922007A (en) *	1989-06-09	1990-05-01	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
JP2974722B2 (ja) *	1990-04-03	1999-11-10	帝国臓器製薬株式会社	カルシトニン注射液
US5019651A (en) *	1990-06-20	1991-05-28	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) *	1991-12-17	1993-12-14	Merck & Co., Inc.	Prevention and treatment of periodontal disease with alendronate
AU5953894A (en) *	1992-12-23	1994-07-19	Merck & Co., Inc.	Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5462932A (en) *	1994-05-17	1995-10-31	Merck & Co., Inc.	Oral liquid alendronate formulations
US5780455A (en) *	1994-08-24	1998-07-14	Merck & Co., Inc.	Intravenous alendronate formulations

1994
- 1994-08-24 US US08/296,192 patent/US5780455A/en not_active Expired - Fee Related
1995
- 1995-08-21 ES ES95929625T patent/ES2216017T3/es not_active Expired - Lifetime
- 1995-08-21 WO PCT/US1995/010583 patent/WO1996005842A1/en not_active Ceased
- 1995-08-21 CA CA002197210A patent/CA2197210C/en not_active Expired - Fee Related
- 1995-08-21 PT PT95929625T patent/PT777484E/pt unknown
- 1995-08-21 EP EP95929625A patent/EP0777484B1/de not_active Expired - Lifetime
- 1995-08-21 JP JP50823396A patent/JP3962429B2/ja not_active Expired - Fee Related
- 1995-08-21 DE DE69532810T patent/DE69532810T2/de not_active Expired - Lifetime
- 1995-08-21 AU AU33320/95A patent/AU698411B2/en not_active Ceased
- 1995-08-21 AT AT95929625T patent/ATE262909T1/de not_active IP Right Cessation
1998
- 1998-03-02 US US09/033,015 patent/US5843924A/en not_active Expired - Fee Related
- 1998-05-05 US US09/072,602 patent/US5914323A/en not_active Expired - Fee Related
2003
- 2003-09-03 JP JP2003311481A patent/JP4177208B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US5780455A (en)	1998-07-14
PT777484E (pt)	2004-06-30
EP0777484A1 (de)	1997-06-11
JP3962429B2 (ja)	2007-08-22
JPH10504574A (ja)	1998-05-06
DE69532810D1 (de)	2004-05-06
JP4177208B2 (ja)	2008-11-05
JP2004075690A (ja)	2004-03-11
AU698411B2 (en)	1998-10-29
EP0777484B1 (de)	2004-03-31
US5843924A (en)	1998-12-01
CA2197210C (en)	2008-02-19
DE69532810T2 (de)	2005-02-17
EP0777484A4 (de)	1998-08-05
AU3332095A (en)	1996-03-14
ES2216017T3 (es)	2004-10-16
WO1996005842A1 (en)	1996-02-29
CA2197210A1 (en)	1996-02-29
US5914323A (en)	1999-06-22

Legal Events

Date

Code

Title

Description

2004-12-15

UEP

Publication of translation of european patent specification

Ref document number: 0777484

Country of ref document: EP

2011-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE262909T1 (de)	2004-04-15	Intravenöse alendronatformulierungen
Nishimura et al.	1995	Auricular prostheses and osseointegrated implants: UCLA experience
DK0527835T3 (da)	1995-04-18	Doseringsform til afgivelse af et anti-Parkinsonmiddel
DK1123094T3 (da)	2007-08-20	Terapeutiske præparater (II)
BR9813524A (pt)	2002-02-19	Processos para tratamento de toxicidades associadas com a administração de um agente terapêutico a um mamìfero, para tratamento de toxicidades associadas com a exposição de um mamìfero à terapia de radiação, para tratamento de neuro- ou nefrodistúrbios em um humano, e, para tratamento de distúrbios e sintomas clìnicos associados com diabetes do tipo i ou do tipo ii em um humano
DK0759757T3 (da)	2002-10-07	Orale, væskeformige alendronatformuleringer
RU94046316A (ru)	1996-10-20	Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
NO20034684D0 (no)	2003-10-20	Innretning for administrering av midler gjennom stratum corcum
DK0833643T3 (da)	2005-05-30	Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
HUP0100437A2 (hu)	2002-05-29	Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
SE8704248D0 (sv)	1987-10-30	Medical use
BG104797A (en)	2001-07-31	Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
DK0629400T3 (da)	2000-02-14	Idebenon-holdige præparater til behandling af Alzheimer's syge
BR0009380A (pt)	2001-12-26	Tratamento de câncer melhorado comtemozolomida
GR3032224T3 (en)	2000-04-27	Therapeutic agent for threatened abortion.
ATE281157T1 (de)	2004-11-15	Zusammensetzung enthaltend di- und trinatriumsalze von echinochrome zur behandlung von augenerkrankungen
MXPA05010804A (es)	2006-03-09	Torio 227 para uso en radioterapia de enfermedades del tejido blando.
PT1251850E (pt)	2006-10-31	Utilizacao de uma preparacao de combinacao na terapia do cancro
SE9101341D0 (sv)	1991-05-03	New medicinal use
FR2635006B1 (fr)	1990-10-19	Medicament destine a regulariser les secretions hormonales et a traiter la sterilite
UA30251A (uk)	2000-11-15	Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи
SANADA et al.	1986	Clinical histories before hospitalization in gastric cancer cases
PT1265629E (pt)	2006-09-29	Utilizacao da hormona de crescimento em dose baixa
Mazor et al.	1990	Conservative periodontal treatment combined with orthodontics for" hopeless" anterior teeth. A case report
RU2000110690A (ru)	2002-02-10	Способ антибиотикотерапии